126 related articles for article (PubMed ID: 18950837)
1. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Shen Y; Lozano M; Swanson DA; Jonasch E; Wood CG
Urology; 2009 Feb; 73(2):337-41. PubMed ID: 18950837
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of thalidomide for patients with advanced renal cell carcinoma.
Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M
J Clin Oncol; 2002 Jan; 20(1):302-6. PubMed ID: 11773183
[TBL] [Abstract][Full Text] [Related]
7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
Repmann R; Goldschmidt AJ; Richter A
Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Amato R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):33-6. PubMed ID: 11204672
[TBL] [Abstract][Full Text] [Related]
10. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Srinivas S; Guardino AE
BJU Int; 2005 Sep; 96(4):536-9. PubMed ID: 16104906
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).
Passalacqua R; Caminiti C; Buti S; Porta C; Camisa R; Braglia L; Tomasello G; Vaglio A; Labianca R; Rondini E; Sabbatini R; Nastasi G; Artioli F; Prati A; Potenzoni M; Pezzuolo D; Oliva E; Alberici F; Buzio C;
J Immunother; 2014; 37(9):440-7. PubMed ID: 25304727
[TBL] [Abstract][Full Text] [Related]
12. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Clark JI; Atkins MB; Urba WJ; Creech S; Figlin RA; Dutcher JP; Flaherty L; Sosman JA; Logan TF; White R; Weiss GR; Redman BG; Tretter CP; McDermott D; Smith JW; Gordon MS; Margolin KA
J Clin Oncol; 2003 Aug; 21(16):3133-40. PubMed ID: 12810695
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
15. Continuing education: The emergence of thalidomide in treating advanced renal cell carcinoma.
Wood LS; Perez C; Monroe D
Oncol Nurs Forum; 2003; 30(3):501-11. PubMed ID: 12719749
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
[TBL] [Abstract][Full Text] [Related]
17. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
19. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
20. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Itano NB; Blute ML; Spotts B; Zincke H
J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]